Nasonex Nasal Spray (mometasone furoate monohydrate) is a prescription corticosteroid spray designed to manage and prevent symptoms of allergic rhinitis, both seasonal and perennial. It works directly in the nasal passages to reduce inflammation, providing significant and sustained relief from congestion, sneezing, runny nose, and nasal itching. Trusted by healthcare professionals, it offers a targeted approach with a favorable safety profile for appropriate patients.

Features

• Active ingredient: Mometasone furoate monohydrate (equivalent to 50 mcg mometasone furoate per spray)
• Delivery system: Metered-dose, manual pump spray bottle
• Preservative: Benzalkonium chloride
• Available in 17g and 60g bottle sizes, delivering 60 and 120 sprays respectively
• pH-balanced formulation for minimal nasal irritation
• Designed for once-daily dosing after initial loading period

Benefits

• Reduces nasal inflammation at the source, addressing the underlying cause of symptoms
• Provides 24-hour relief from congestion, sneezing, runny nose, and itching with single daily use
• Prevents allergy symptoms when used regularly before allergen exposure
• Non-drowsy formula allows for unimpaired daytime function
• Suitable for long-term management of chronic allergic rhinitis
• Improves quality of life by restoring normal nasal breathing and sleep patterns

Common use

Nasonex Nasal Spray is primarily indicated for the treatment of seasonal and perennial allergic rhinitis symptoms in adults and pediatric patients 2 years and older. It is also approved for the prophylaxis of seasonal allergic rhinitis symptoms in adults and adolescents 12 years and older when started 2-4 weeks prior to anticipated pollen season. Additionally, it may be used as adjunctive therapy for nasal polyps in patients 18 years and older.

Dosage and direction

For allergic rhinitis in adults and children 12 years and older: 2 sprays in each nostril once daily (total 200 mcg/day). When symptoms are controlled, dose may be reduced to 1 spray in each nostril once daily. For children 2-11 years: 1 spray in each nostril once daily (total 100 mcg/day). For seasonal allergic rhinitis prophylaxis: Begin 2-4 weeks before anticipated pollen season. Shake well before use. Prime pump before first use by actuating 10 times until fine spray appears. If not used for 14 days or longer, reprime with 2 sprays or until fine spray appears.

Precautions

Use with caution in patients with recent nasal septum ulcers, nasal surgery, or nasal trauma until healed. Monitor patients for evidence of nasal candidiasis. Avoid use in patients with active or quiescent tuberculosis infections, untreated fungal, bacterial, or viral systemic infections, or ocular herpes simplex. Periodic examinations of the nasal mucosa are recommended during prolonged treatment. May cause slowed growth in children; monitor growth routinely. Use the smallest effective dose to minimize systemic effects.

Contraindications

Hypersensitivity to mometasone furoate or any component of the formulation. Not for use in patients with untreated localized nasal infections. Contraindicated in patients with untreated fungal, bacterial, or viral systemic infections. Should not be used during an acute asthma attack or other acute episodes where intensive measures are required.

Possible side effects

Most common side effects include headache (8%), viral infection (4%), pharyngitis (4%), epistaxis (4%), and coughing (3%). Less common side effects may include nasal burning/irritation, nasal ulceration, nasal septal perforation, impaired wound healing, blurred vision, glaucoma, cataracts with long-term use, and adrenal suppression with excessive doses. Immediate hypersensitivity reactions including urticaria, angioedema, rash, and bronchospasm may occur rarely.

Drug interaction

No formal drug interaction studies have been conducted with Nasonex Nasal Spray. However, caution is advised when coadministering with other corticosteroids due to potential additive systemic effects. Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase mometasone plasma concentrations. Monitor patients closely for signs of hypercorticism when used concomitantly with other corticosteroids or CYP3A4 inhibitors.

Missed dose

If a dose is missed, use it as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Maintain consistent daily use for optimal symptom control, particularly for prophylactic use during allergy season.

Overdose

Acute overdose with Nasonex Nasal Spray is unlikely due to low systemic bioavailability. However, chronic excessive use may lead to systemic corticosteroid effects including hypercorticism and adrenal suppression. In case of chronic overdose, discontinue treatment gradually and provide supportive care. Monitor adrenal function in cases of significant overdose. There is no specific antidote; treatment should be symptomatic and supportive.

Storage

Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze. Keep bottle upright and protected from light. Discard 120 days after opening or when the counter reads “0”, whichever comes first. Keep out of reach of children. Do not store in extreme temperatures or direct sunlight.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medication. Proper diagnosis and treatment recommendations should come from a licensed physician. Individual results may vary based on patient-specific factors and adherence to prescribed regimen.

Reviews

Clinical studies demonstrate Nasonex Nasal Spray significantly improves total nasal symptom scores compared to placebo, with onset of action within 12 hours for some symptoms and maximal effect within 2 days. In pediatric studies, patients showed significant improvement in nasal symptoms with once-daily dosing. Long-term studies (up to 12 months) show maintained efficacy with no evidence of tachyphylaxis. Patient satisfaction surveys indicate high rates of satisfaction with symptom control and convenience of once-daily dosing.